These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 35216737)

  • 1. Response to Letter to the Editor Titled "Focusing on Intrathecal Pemetrexed for Treating Leptomeningeal Metastases from NSCLC?".
    Fan C; Zhao Q; Teng C; Jiang Z; Xin T
    J Thorac Oncol; 2022 Mar; 17(3):e33-e34. PubMed ID: 35216737
    [No Abstract]   [Full Text] [Related]  

  • 2. Focusing on Intrathecal Pemetrexed for Treating Leptomeningeal Metastases From NSCLC.
    Pan Z
    J Thorac Oncol; 2022 Mar; 17(3):e31-e32. PubMed ID: 35216736
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of intrathecal pemetrexed for TKI-failed leptomeningeal metastases from EGFR+ NSCLC: an expanded, single-arm, phase II clinical trial.
    Fan C; Jiang Z; Teng C; Song X; Li L; Shen W; Jiang Q; Huang D; Lv Y; Du L; Wang G; Hu Y; Man S; Zhang Z; Gao N; Wang F; Shi T; Xin T
    ESMO Open; 2024 Apr; 9(4):102384. PubMed ID: 38377785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrathecal Pemetrexed: Another Potential Treatment Modality for Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases?
    Zheng MM; Li YS; Sun H; Chen HJ; Wu YL
    J Thorac Oncol; 2021 Oct; 16(10):e82-e84. PubMed ID: 34561041
    [No Abstract]   [Full Text] [Related]  

  • 5. Response to Letter to the Editor Titled "Intrathecal Pemetrexed: Another Potential Treatment Modality for TKI-Failed Leptomeningeal Metastases?".
    Fan C; Zhao Q; Jiang Z; Xin T
    J Thorac Oncol; 2021 Oct; 16(10):e85. PubMed ID: 34561042
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and Safety of Intrathecal Pemetrexed Combined With Dexamethasone for Treating Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases From EGFR-Mutant NSCLC-a Prospective, Open-Label, Single-Arm Phase 1/2 Clinical Trial (Unique Identifier: ChiCTR1800016615).
    Fan C; Zhao Q; Li L; Shen W; Du Y; Teng C; Gao F; Song X; Jiang Q; Huang D; Jin Y; Lv Y; Wei L; Shi T; Zhao X; Gao N; Jiang Z; Xin T
    J Thorac Oncol; 2021 Aug; 16(8):1359-1368. PubMed ID: 33989780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment response to intrathecal chemotherapy with pemetrexed via an Ommaya reservoir in EGFR-mutated leptomeningeal metastases from non-small cell lung cancer: a case report.
    Li H; Lin Y; Yu T; Xie Y; Feng J; Huang M; Guo A; Liu X; Yin Z
    Ann Palliat Med; 2020 Jul; 9(4):2341-2346. PubMed ID: 32648459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brief Report: EGFR L833V/H835L Duplex-Mutated NSCLC With Leptomeningeal Carcinomatosis Responsive to Osimertinib.
    Smith JT; Puri S; Akerley W
    Clin Lung Cancer; 2023 Jun; 24(4):360-361. PubMed ID: 36935243
    [No Abstract]   [Full Text] [Related]  

  • 9. Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases.
    Flippot R; Biondani P; Auclin E; Xiao D; Hendriks L; Le Rhun E; Leduc C; Beau-Faller M; Gervais R; Remon J; Adam J; Planchard D; Lavaud P; Naltet C; Caramella C; Le Pechoux C; Lacroix L; Gazzah A; Mezquita L; Besse B
    J Thorac Oncol; 2019 Aug; 14(8):1400-1407. PubMed ID: 31108248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, Pharmacokinetic and Clinical Activity of Intrathecal Chemotherapy With Pemetrexed via the Ommaya Reservoir for Leptomeningeal Metastases From Lung Adenocarcinoma: A Prospective Phase I Study.
    Li H; Zheng S; Lin Y; Yu T; Xie Y; Jiang C; Liu X; Qian X; Yin Z
    Clin Lung Cancer; 2023 Mar; 24(2):e94-e104. PubMed ID: 36588048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era.
    Riess JW; Nagpal S; Iv M; Zeineh M; Gubens MA; Ramchandran K; Neal JW; Wakelee HA
    Clin Lung Cancer; 2014 May; 15(3):202-6. PubMed ID: 24524822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer.
    Choi M; Keam B; Ock CY; Kim M; Kim TM; Kim DW; Heo DS
    Clin Lung Cancer; 2019 Jul; 20(4):e442-e451. PubMed ID: 31010639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remarkable response to dacomitinib in a patient with leptomeningeal carcinomatosis due to EGFR-mutant non-small cell lung cancer.
    Mizusaki S; Otsubo K; Ninomiya T; Arimura H; Tsuchiya-Kawano Y; Inoue K
    Thorac Cancer; 2021 Jan; 12(1):114-116. PubMed ID: 33112047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor.
    Kwon BS; Cho YH; Yoon SK; Lee DH; Kim SW; Kwon DH; Lee JC; Choi CM
    Thorac Cancer; 2020 Feb; 11(2):436-442. PubMed ID: 31910497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical trials on intrathecal pemetrexed treated leptomeningeal metastases from solid tumors].
    Pan ZY; Song YY; Jiang TC; Yang X; Yang GZ
    Zhonghua Zhong Liu Za Zhi; 2022 Jan; 44(1):112-119. PubMed ID: 35073657
    [No Abstract]   [Full Text] [Related]  

  • 16. High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases--one with a remarkable thoracic response as well.
    Kuiper JL; Smit EF
    Lung Cancer; 2013 Apr; 80(1):102-5. PubMed ID: 23375403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR exon 19 deletion mutations and systemic/central nervous system miliary metastasis: clinical correlations and response to therapy.
    Poonia S; Berge EM; Aisner DL; Damek D; Doebele RC
    Clin Lung Cancer; 2014 Sep; 15(5):387-9. PubMed ID: 24894944
    [No Abstract]   [Full Text] [Related]  

  • 18. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis.
    Liao BC; Lee JH; Lin CC; Chen YF; Chang CH; Ho CC; Shih JY; Yu CJ; Yang JC
    J Thorac Oncol; 2015 Dec; 10(12):1754-61. PubMed ID: 26334749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis.
    Ahn HK; Han B; Lee SJ; Lim T; Sun JM; Ahn JS; Ahn MJ; Park K
    Lung Cancer; 2012 May; 76(2):253-4. PubMed ID: 22385925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of nonsmall cell lung cancer patients with leptomeningeal metastases using whole brain radiotherapy and tyrosine kinase inhibitors.
    Sakaguchi M; Maebayashi T; Aizawa T; Ishibashi N; Saito T
    J Cancer Res Ther; 2020; 16(4):930-932. PubMed ID: 32930144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.